Splenectomy and thrombosis: The case of thalassemia intermedia

Journal of Thrombosis and Haemostasis

Volumn 8, Issue 10, 2010, Pages 2152-2158

  Taher, A T ^a   Musallam, K M ^a   Karimi, M ^b   El Beshlawy, A ^c   Belhoul, K ^d   Daar, S ^e   Saned, M ^d   Cesaretti, C ^f   Cappellini, M D ^f  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c CAIRO UNIVERSITY   (Egypt)

^d Al Wasl Hospital   (United Arab Emirates)

^e SULTAN QABOOS UNIVERSITY   (Oman)

^f UNIVERSITY OF MILAN   (Italy)

Author keywords

Hypercoagulability; Splenectomy; Thalassemia intermedia; Thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; HYDROXYUREA;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD TRANSFUSION; CHILD; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DEMOGRAPHY; ERYTHROCYTE COUNT; FEMALE; HUMAN; ITALY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MIDDLE EAST; PORTAL VEIN THROMBOSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RETROSPECTIVE STUDY; SCHOOL CHILD; SPLENECTOMY; SUPERFICIAL THROMBOPHLEBITIS; THALASSEMIA; THALASSEMIA INTERMEDIA; THROMBOCYTE COUNT; THROMBOEMBOLISM;

ADOLESCENT; ADULT; AGED; BETA-THALASSEMIA; BLOOD COAGULATION; CHILD; CODON; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; RETROSPECTIVE STUDIES; SPLENECTOMY; STROKE; THROMBOEMBOLISM; THROMBOSIS;

EID: 78649339507     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2010.03940.x     Document Type: Article

References (44)

1. Weatherall DJ, Clegg JB. The Thalassaemia Syndromes. Oxford; Malden, MA: Blackwell Science, 2001.
2. Rund D, Rachmilewitz E. Beta-thalassemia. N Engl J Med 2005; 353: 1135-46.
3. Sturgeon P, Itano HA, Bergren WR. Genetic and biochemical studies of intermediate types of Cooley's anaemia. Br J Haematol 1955; 1: 264-77.
4. Taher A, Isma'eel H, Cappellini MD. Thalassemia intermedia: revisited. Blood Cells Mol Dis 2006; 37: 12-20.
5. Taher AT, Musallam KM, Karimi M, El-Beshlawy A, Belhoul K, Daar S, Saned MS, El-Chafic AH, Fasulo MR, Cappellini MD. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood 2010; 115: 1886-92.
6. Borgna Pignatti C, Carnelli V, Caruso V, Dore F, De Mattia D, Di Palma A, Di Gregorio F, Romeo MA, Longhi R, Mangiagli A, Melevendi C, Pizzarelli G, Musumeci S. Thromboembolic events in beta thalassemia major: an Italian multicenter study. Acta Haematol 1998; 99: 76-9.
7. Taher A, Isma'eel H, Mehio G, Bignamini D, Kattamis A, Rachmilewitz EA, Cappellini MD. Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran. Thromb Haemost 2006; 96: 488-91.
8. Taher AT, Otrock ZK, Uthman I, Cappellini MD. Thalassemia and hypercoagulability. Blood Rev 2008; 22: 283-92.
9. Crary SE, Buchanan GR. Vascular complications after splenectomy for hematologic disorders. Blood 2009; 114: 2861-8.
10. Cappellini MD, Robbiolo L, Bottasso BM, Coppola R, Fiorelli G, Mannucci AP. Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia. Br J Haematol 2000; 111: 467-73.
11. Camaschella C, Cappellini MD. Thalassemia intermedia. Haematologica 1995; 80: 58-68.
12. Barst RJ, McGoon M, Torbicki A, Sitbon O, Krowka MJ, Olschewski H, Gaine S. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: 40S-7S.
13. Kleber FX, Niemoller L, Doering W. Impact of converting enzyme inhibition on progression of chronic heart failure: results of theMunich Mild Heart Failure Trial. Br Heart J 1992; 67: 289-96.
14. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203.
15. Cadili A, de Gara C. Complications of splenectomy. Am J Med 2008; 121: 371-5.
16. Weatherall DJ. The inherited diseases of hemoglobin are an emerging global health burden. Blood 2010. DOI: 10.1182/blood-2010-01-251348. Epub ahead of print.
17. Shinar E, Rachmilewitz EA, Lux SE. Differing erythrocyte membrane skeletal protein defects in alpha and beta thalassemia. J Clin Invest 1989; 83: 404-10.
18. Hershko C, Graham G, Bates GW, Rachmilewitz EA. Non-specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity. Br J Haematol 1978; 40: 255-63.
19. Kuypers FA, de Jong K. The role of phosphatidylserine in recognition and removal of erythrocytes. Cell Mol Biol (Noisy-le-grand) 2004; 50: 147-58.
20. Tavazzi D, Duca L, Graziadei G, Comino A, Fiorelli G, Cappellini MD. Membrane-bound iron contributes to oxidative damage of betathalassaemia intermedia erythrocytes. Br J Haematol 2001; 112: 48-50.
21. Borenstain-Ben Yashar V, Barenholz Y, Hy-Am E, Rachmilewitz EA, Eldor A. Phosphatidylserine in the outer leaflet of red blood cells from beta-thalassemia patients may explain the chronic hypercoagulable state and thrombotic episodes. Am J Hematol 1993; 44: 63-5.
22. Helley D, Eldor A, Girot R, Ducrocq R, Guillin MC, Bezeaud A. Increased procoagulant activity of red blood cells from patients with homozygous sickle cell disease and beta-thalassemia. Thromb Haemost 1996; 76: 322-7.
23. Atichartakarn V, Angchaisuksiri P, Aryurachai K, Onpun S, Chuncharunee S, Thakkinstian A, Atamasirikul K. Relationship between hypercoagulable state and erythrocyte phosphatidylserine exposure in splenectomized haemoglobin E/beta-thalassaemic patients. Br J Haematol 2002; 118: 893-8.
24. Habib A, Kunzelmann C, Shamseddeen W, Zobairi F, Freyssinet JM, Taher A. Elevated levels of circulating procoagulant microparticles in patients with beta-thalassemia intermedia. Haematologica 2008; 93: 941-2.
25. Chen S, Eldor A, Barshtein G, Zhang S, Goldfarb A, Rachmilewitz E, Yedgar S. Enhanced aggregability of red blood cells of beta-thalassemia major patients. Am J Physiol 1996; 270: H1951-6.
26. Taher AT, Musallam KM, Nasreddine W, Hourani R, Inati A, Beydoun A. Asymptomatic brain magnetic resonance imaging abnormalities in splenectomized adults with thalassemia intermedia. J Thromb Haemost 2010; 8: 54-9.
27. Aessopos A, Kati M, Meletis J. Thalassemia intermedia today: should patients regularly receive transfusions? Transfusion 2007; 47: 792-800.
28. Cossu P, Toccafondi C, Vardeu F, Sanna G, Frau F, Lobrano R, Cornacchia G, Nucaro A, Bertolino F, Loi A, De Virgiliis S, Cao A. Iron overload and desferrioxamine chelation therapy in beta-thalassemia intermedia. Eur J Pediatr 1981; 137: 267-71.
29. PippardMJ, Weatherall DJ. Iron balance and the management of iron overload in beta-thalassemia intermedia. Birth Defects Orig Artic Ser 1988; 23: 29-33.
30. Pootrakul P, Sirankapracha P, Sankote J, Kachintorn U, Maungsub W, Sriphen K, Thakernpol K, Atisuk K, Fucharoen S, Chantraluksri U, Shalev O, Hoffbrand AV. Clinical trial of deferiprone iron chelation therapy in beta-thalassaemia/haemoglobin E patients in Thailand. Br J Haematol 2003; 122: 305-10.
31. Voskaridou E, Plata E, Douskou M, Papadakis M, Delaki EE, Christoulas D, Terpos E. Treatment with deferasirox (Exjade) effectively decreases iron burden in patients with thalassaemia intermedia: results of a pilot study. Br J Haematol 2010; 148: 332-4.
32. Winichagoon P, Fucharoen S, Wasi P. Increased circulating platelet aggregates in thalassaemia. Southeast Asian J TropMed Public Health 1981; 12: 556-60.
33. Del Principe D, Menichelli A, Di Giulio S, De Matteis W, Cianciulli P, Papa G. PADGEM/GMP-140 expression on plateletmembranes from homozygous beta thalassaemic patients. Br J Haematol 1993; 84: 111-7.
34. Ruf A, Pick M, Deutsch V, Patscheke H, Goldfarb A, Rachmilewitz EA, Guillin MC, Eldor A. In-vivo platelet activation correlates with red cell anionic phospholipid exposure in patients with beta-thalassaemia major. Br J Haematol 1997; 98: 51-6.
35. Eldor A, Lellouche F, Goldfarb A, Rachmilewitz EA, Maclouf J. In vivo platelet activation in beta-thalassemia major reflected by increased platelet-thromboxane urinary metabolites. Blood 1991; 77: 1749-53.
36. Cappellini MD, Grespi E, Cassinerio E, Bignamini D, Fiorelli G. Coagulation and splenectomy: an overview. Ann N Y Acad Sci 2005; 1054: 317-24.
37. Gladwin MT, Vichinsky E. Pulmonary complications of sickle cell disease. N Engl J Med 2008; 359: 2254-65.
38. Isma'eel H, Chafic AH, Rassi FE, Inati A, Koussa S, Daher R, Gharzuddin W, Alam S, Taher A. Relation between iron-overload indices, cardiac echo-Doppler, and biochemicalmarkers in thalassemia intermedia. Am J Cardiol 2008; 102: 363-7.
39. Sonakul D, Pacharee P, Laohapand T, Fucharoen S, Wasi P. Pulmonary artery obstruction in thalassaemia. Southeast Asian J Trop Med Public Health 1980; 11: 516-23.
40. Sumiyoshi A, Thakerngpol K, Sonakul D. Pulmonary microthromboemboli in thalassemic cases. Southeast Asian J Trop Med Public Health 1992; 23(Suppl 2): 29-31.
41. O'Donnell A, Premawardhena A, Arambepola M, Allen SJ, Peto TE, Fisher CA, Rees DC, Olivieri NF, Weatherall DJ. Age-related changes in adaptation to severe anemia in childhood in developing countries. Proc Natl Acad Sci USA 2007; 104: 9440-4.
42. Aessopos A, Farmakis D, Karagiorga M, Voskaridou E, Loutradi A, Hatziliami A, Joussef J, Rombos J, Loukopoulos D. Cardiac involvement in thalassemia intermedia: a multicenter study. Blood 2001; 97: 3411-6.
43. Aessopos A, Farmakis D, Deftereos S, Tsironi M, Tassiopoulos S, Moyssakis I, KaragiorgaM. Thalassemia heart disease: a comparative evaluation of thalassemia major and thalassemia intermedia. Chest 2005; 127: 1523-30.
44. Derchi G, Forni GL, Formisano F, Cappellini MD, Galanello R, D'Ascola G, Bina P, Magnano C, Lamagna M. Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathies. Haematologica 2005; 90: 452-8.